-
AZ505: Selective SMYD2 Inhibitor Workflow
2026-09-02
A scenario-based guide to using AZ505, a potent and selective SMYD2 inhibitor, in cell viability, proliferation, and cytotoxicity workflows. It explains how SKU B1255 links biochemical potency with practical controls, model selection, data interpretation, and vendor reliability.
-
Dual Luciferase Reporter Gene System for Al Stress
2026-09-02
Learn how a Dual Luciferase Reporter Gene System can convert the tomato SlSTOP1–SlSLAH1 aluminium-tolerance mechanism into a rigorous promoter-testing strategy. This article emphasizes reporter architecture, normalization limits, and the practical boundaries of applying mammalian-cell reagents to plant regulatory biology.
-
Ganetespib (STA-9090) Workflow for Hsp90 Studies
2026-09-01
Ganetespib (STA-9090) combines a non-geldanamycin scaffold with potent Hsp90 inhibition, making it useful for connecting client-protein destabilization to cancer-cell phenotypes. This guide translates that mechanism into practical dose-response, target-engagement, release-assay, and troubleshooting workflows while clearly separating oncology evidence from a recent virology insight.
-
Z-DEVD-FMK: Caspase-3 Inhibitor Workflows
2026-09-01
Z-DEVD-FMK enables controlled dissection of apoptosis, caspase signaling, and calpain-linked proteolysis in cell and neurobiology models. Its use in SADS-CoV research also shows how a caspase-3 inhibitor can connect programmed cell death with antiviral innate-immunity assays.
-
Rimonabant (SR141716) for CB1 Mechanism Studies
2026-08-31
Rimonabant (SR141716) gives researchers a selective CB1 blockade tool for separating cannabinoid-dependent signaling from appetite, inflammatory, and pain-related phenotypes. Its strongest use is as a mechanistic comparator in carefully controlled cell, feeding, and neuropathic-pain workflows—not as a substitute for pathway-specific validation.
-
LGK-974: A Practical PORCN Inhibitor Workflow
2026-08-31
A practical guide to using LGK-974 as a PORCN inhibitor for Wnt-dependent cancer models and mechanistic bone research. The workflow connects nanomolar pathway control with target-engagement readouts, dose optimization, and troubleshooting for reproducible experiments.
-
Oseltamivir acid for Reliable Cell Assays
2026-08-30
Oseltamivir acid (SKU A3689) offers a practical way to standardize neuraminidase-inhibition studies, stock preparation, and viability or cytotoxicity workflows. This scenario-based guide connects product specifications with influenza antiviral research, resistance-aware interpretation, and carefully bounded oncology applications.
-
4-Ethylphenyl Sulfate: Assay Design Guide
2026-08-29
Explore how 4-ethylphenyl sulfate connects renal toxin profiling with gut microbiota-brain interaction research. This evidence-based guide translates adsorption findings, chemical specifications, and preclinical neurobehavioral data into practical assay decisions.
-
MK-5108: AURKA Evidence in Retinoblastoma
2026-08-28
MK-5108 (VX-689) is a highly selective Aurora A inhibitor for testing mitotic dependence in cancer models. This article connects retinoblastoma biology with evidence-driven assay selection, model validation, and xenograft interpretation.
-
Substrate Stiffness and LAMB1–FAK–MEK1/2 Dentinogenesis
2026-08-28
The reference study shows that substrate stiffness can promote dentinogenesis in odontoblast-like cells through a LAMB1–FAK–MEK1/2 mechanotransduction axis. Its combination of tunable PDMS substrates, mineralization assays, gene-expression analysis, and protein-interaction studies provides a framework for linking material mechanics to reparative dentin formation.
-
BI 2536: Reading PLK1 Checkpoint Biology
2026-08-27
BI 2536 is a selective PLK1 inhibitor that can reveal how mitotic arrest, checkpoint disassembly, and apoptosis are mechanistically connected. This article translates the p31comet–PLK1 study into a deeper framework for interpreting cancer research assays and tumor models.
-
AmpliFold Capture-and-Release for LFA Sensitivity
2026-08-27
The ChemRxiv study introduces AmpliFold, a triggered capture-and-release strategy that uses cleavable protein linkers and dual-affinity gold nanoparticles to improve lateral flow assay sensitivity. In a HER2 model, expanding the capture area and tuning receptor density produced up to 16-fold improvement in detection performance, including a 12-fold enhancement with 150 nm nanoparticles in buffer and human serum.
-
CCT007093: PPM1D Inhibitor Workflows
2026-08-26
CCT007093 is a research-use PPM1D inhibitor for connecting phosphatase activity with early P38 kinase activation, cell viability, and inflammatory cell-death readouts. Its strongest use is an orthogonal workflow that combines biochemical testing, timed phospho-P38 analysis, viability measurements, and pathway-rescue controls.
-
Tunicamycin as an ER Stress Assay Compass
2026-08-26
Tunicamycin is a powerful N-glycosylation inhibitor for dissecting how ER stress reshapes endothelial inflammation. This guide translates recent ATF6–TRIM10–NF-κB findings into practical assay design, controls, and interpretation strategies.
-
CB-5083 p97 Inhibitor Workflows in Cancer Research
2026-08-25
CB-5083 converts p97 biology into a practical workflow for measuring protein homeostasis disruption, stress signaling, and cancer cell apoptosis induction. This guide links biochemical target engagement with cell-based assays, cGAS–DNA repair studies, and tumor growth inhibition in xenograft models while emphasizing reproducible handling and troubleshooting.